Cooley: T-Therapeutics Announces Oversubscribed $133 Million Series B
November 06, 2026
November 06, 2026
PALO ALTO, California, Nov. 6 -- Cooley, a law firm, issued the following news release:
* * *
T-Therapeutics Announces Oversubscribed $133 Million Series B
London November 5, 2026
Cooley advised T-Therapeutics, a biotechnology company developing next-generation T cell receptor (TCR) T cell engager (TCE) for cancer and autoimmune diseases, on the closing of an oversubscribed $133 million Series B. The financing was co-led by Advent Life Sciences . . .
* * *
T-Therapeutics Announces Oversubscribed $133 Million Series B
London November 5, 2026
Cooley advised T-Therapeutics, a biotechnology company developing next-generation T cell receptor (TCR) T cell engager (TCE) for cancer and autoimmune diseases, on the closing of an oversubscribed $133 million Series B. The financing was co-led by Advent Life Sciences . . .